CNC · Centene Corp
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted earnings per share non-GAAP | $2.51 | Q2 2026 | — |
|
|
|||
| Adjusted SG&A expense ratio non-GAAP | 7.2% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Commercial HBR | 77.2% | Six Months Ended June 30, 2026 | — |
| Days in claims payable | 47 | Q2 2026 | — |
|
|
|||
| Debt to capitalization | 41.6% | Q2 2026 | — |
|
|
|||
| HBR | 88.4% | Six Months Ended June 30, 2026 | — |
|
|
|||
| High Acuity Medicaid | 1,364,900 | Q2 2026 | — |
| Individual and Commercial Group | 497,000 | Q2 2026 | — |
| Marketplace | 3,494,700 | Q2 2026 | — |
|
|
|||
| Medicaid HBR | 93.5% | Six Months Ended June 30, 2026 | — |
| Medicare | 980,000 | Q2 2026 | — |
|
|
|||
| Medicare HBR | 87.3% | Six Months Ended June 30, 2026 | — |
| Medicare PDP | 8,803,000 | Q2 2026 | — |
|
|
|||
| Medicare segment HBR | 89.5% | Q2 2026 | — |
| Number of employees | 59,800 | Q2 2026 | — |
|
|
|||
| Regulated cash, investments and restricted deposits | $43.02B | Q2 2026 | — |
| SG&A expense ratio | 7.3% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Total at-risk membership | 25,885,400 | Q2 2026 | — |
|
|
|||
| Total cash, investments and restricted deposits | $44.85B | Q2 2026 | — |
| Total Commercial | 3,991,700 | Q2 2026 | — |
|
|
|||
| Total Medicaid | 12,110,700 | Q2 2026 | — |
|
|
|||
| Traditional Medicaid | 10,745,800 | Q2 2026 | — |
| Unregulated cash, investments and restricted deposits | $1.83B | Q2 2026 | — |
| Health benefits ratio | 87.3% | Q1 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNC
this stock
Centene Corp
|
$32.12B | +58.0% | +19.4% | — | 2.8% |
|
UNH
Unitedhealth Group Inc
|
$350.16B | +18.2% | +11.8% | — | 1.7% |
|
CVS
CVS HEALTH Corp
|
$118.97B | +17.2% | +7.8% | 24.5 | 1.5% |
|
ELV
Elevance Health, Inc.
|
$86.86B | +14.3% | +12.5% | 17.7 | 2.6% |
|
CI
Cigna Group
|
$73.33B | +0.8% | +11.2% | 11.5 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNC | -3.6% | +2.5% | +45.8% | +4.5% | +58.0% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -2.3% | -1.1% | +34.2% | +2.0% | +45.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.